TickerTalks
Browse all tickers →
TickerTalks›$COGZF
COCOGZF

Cogstate Limited

$COGZF·$357M·Medical - Healthcare Information Services·Healthcare
$2.400.0%1Y+105.1%
Mentions · last 7 days
2026-08-21: 0 posts2026-08-22: 0 posts2026-08-23: 0 posts10%
Price updated 2m ago·X counts updated 8d ago
COCOGZF
$COGZFCogstate Limited
$2.400.00%1 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $COGZF, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-29

The move is getting stronger, with heavier trading behind it.

Australian cognitive-assessments provider with +40% forward EPS growth + revenue +39% YoY; at 100% of 52w range.

Cogstate Limited is a $360M Australian-based neuroscience-technology firm (digital cognitive assessments, e-solutions for clinical trials — psychiatry + neurology focus) at $2.40 — +105% t12m, sitting at 100% of its 52w range and +40% above the 200d.

  • Q4 FY26 EPS $0.0415 vs $0.0384 (+8.2% beat), Q2 FY26 $0.026 vs $0.021 (+21.9%), Q2 FY25 $0.037 no est — Q4 was standout.
  • Q4 FY26 revenue $32.3M (+38.9% YoY), Q2 FY26 $26.2M (+39.3%) — real double-digit revenue growth on clinical-trials expansion.
  • Cash economics: PE 30.0, PS 6.05, ROIC 14.5% (attractive), ROE 21.6%, gross margin 34%, op-margin 20.5%, D/E 0.006 (essentially unlevered), EV/EBITDA 21.2, FCF yield 2.5%.
  • Analyst path FY (June) 2026 EPS $0.093 → FY 2027 $0.131 (+40% growth) — real material growth modeled.
  • Recent news: "Cogstate Limited Discusses Clinical Trials Growth Through Indication and Solution Expansion With Focus on Psychiatry and Neurology" — the growth expansion narrative.
  • Structural: 2.40x volume multiplier + +40% vs 200d + 100% of 52w range = confirmed breakout momentum.
  • Sentiment feed is empty.

Read as an Australian-listed digital cognitive-assessments provider with real double-digit revenue growth + FY27 EPS +40% modeled + clinical-trials indication expansion into psychiatry + neurology; the debated question is whether Q3 FY26 confirms the growth pace or whether the 100% of 52w range pricing has exhausted the near-term move.

What to watch: Additional clinical-trial customer wins in psychiatry/neurology, Q1 FY27 revenue trajectory.

On the calendar: 2027-02-24 next earnings

float missingbeta missing

Read the AI verdict + X sentiment for $COGZF

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Cogstate provides technology-enabled cognitive assessments for clinical trials targeting Alzheimer's, ADHD, and other CNS conditions.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $COGZF.

Medical - Healthcare Information Services · Healthcare

Healthcare IT adoption — EHR optimization, AI-assisted coding, and clinical decision support — is the structural demand driver. CMS reimbursement model shifts toward value-based care accelerate analytics and connectivity investment.

What this means for $COGZF

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Industry benchmark

11-name peer basket
+30.0%YTD
+27.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
30.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
14.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
20.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
21.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
33.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 17, 2026$0.04$0.04+8.2%
Q4 2025Feb 18, 2026$0.03$0.02+21.9%
Q2 2025Aug 17, 2025$0.04——
Q4 2024Feb 20, 2025$0.02——
Next earningsWed, Feb 24·consensus EPS $0.04

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY26$32.3M+38.9%38.6%25.8%$0.04$6.2M
Q2 FY26$26.2M+39.3%27.7%14.0%$0.03$2.5M
Q4 FY25$30.0M+32.6%40.9%27.7%$0.04$7.2M
Q2 FY25$23.9M+22.0%60.8%26.6%$0.02$4.9M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$128.5M$126.8M – $130.2M$0.09$0.09 – $0.102
FY27$105.5M$99.0M – $110.6M$0.13$0.12 – $0.143
FY28$120.3M$118.3M – $123.4M$0.15$0.15 – $0.163
FY29$135.8M$130.7M – $140.6M$0.00$0.00 – $0.001
FY30$151.3M$145.7M – $156.7M$0.00$0.00 – $0.001

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.100%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+23.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+40.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cogstate Limited (COGZF) Q4 2026 Earnings Call Transcriptseekingalpha.com·14d agoCogstate Limited (COGZF) Discusses Clinical Trials Growth Through Indication and Solution Expansion With Focus on Psychiatry and Narcolepsy Transcriptseekingalpha.com·82d ago

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$HTFL$TXG$HNGE$DOCS$WGS$TDOC$GEHC
Voices on X · last 7 days

No standout posts about $COGZF on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport